氯胺酮输注用于严重创伤患者疼痛控制:一项随机对照试验的结果
这项前瞻性、随机、双盲、安慰剂对照试验纳入损伤严重度评分(ISS)≥15的18-64岁成人,入住一级创伤中心,排除格拉斯哥昏迷评分<14、ISS<15、妊娠及慢性阿片使用。所有患者均使用患者自控镇痛,并随机接受可调剂量氯胺酮起始3 μg/kg/min或等速率0.9%氯化钠。主要终点为24小时口服吗啡等效量(OME)的减少。可调剂量氯胺酮组与安慰剂组24小时OME中位数分别为110.6(55.7,191.7)和99.2(50.6,172.6),p=0.85;24-48小时及整个48小时研究期间OME均无显著差异;疼痛评分4.9 vs 4.7,p=0.95;因达到无效性界值而终止入组。
要点
- 严重创伤(ISS≥15)成人中,可调剂量氯胺酮起始3 μg/kg/min与安慰剂相比,24小时OME中位数110.6 vs 99.2,p=0.85,无显著差异。
- 24-48小时及整个48小时研究期间OME均无显著差异,疼痛评分4.9 vs 4.7(p=0.95),各时间点均无差异。
- 研究因达到预设无效性界值而提前终止入组,共42/78例(53.8%)随机至试验组。
- 两组中位ISS均为22(19,28.5),基线构成相似。
- 作者认为,需进一步研究以确定辅助氯胺酮在不同创伤亚群中是否有任何获益。
适用人群与场景
- 严重创伤成人患者,年龄18-64岁,ISS≥15,入住一级创伤中心。
- 排除标准:格拉斯哥昏迷评分<14、ISS<15、妊娠、慢性阿片使用。
诊断标准与关键阈值
- 严重创伤定义为损伤严重度评分(ISS)≥15。
- 排除格拉斯哥昏迷评分<14、ISS<15、妊娠及慢性阿片使用。
处置流程与药物剂量
- 所有患者均处方患者自控镇痛,并随机接受可调剂量氯胺酮起始3 μg/kg/min或等速率0.9%氯化钠。
- 研究药物和患者自控镇痛滴定按治疗算法进行。
研究设计与关键结果
- 前瞻性、随机、双盲、安慰剂对照试验,纳入78例严重创伤成人,42例(53.8%)随机至试验组。
- 两组中位ISS均为22(19,28.5),基线构成相似。
- 主要终点24小时OME中位数:可调剂量氯胺酮组110.6(55.7,191.7)vs 安慰剂组99.2(50.6,172.6),p=0.85。
- 24-48小时及整个48小时研究期间OME均无显著差异。
- 疼痛评分:可调剂量氯胺酮组4.9 vs 安慰剂组4.7,p=0.95,研究期间无差异。
- 研究达到无效性界值,终止入组。
证据类型、等级与局限
- 证据类型:前瞻性、随机、双盲、安慰剂对照试验。
- 证据等级:治疗/护理管理;Level I。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在严重创伤(ISS≥15)成人中,可调剂量氯胺酮起始3 μg/kg/min与安慰剂相比未减少24小时OME或疼痛评分,各时间点均无差异。
- 作者认为,需进一步研究以确定辅助氯胺酮在不同创伤亚群中是否有任何获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Opiate-based pain regimens remain the cornerstone of pain management following traumatic injury, but issues related to opioids have driven research into alternative analgesics. Adjunctive ketamine has been increasingly used to decrease opioid use, but little evidence exists to support its efficacy within the trauma population.
METHODS: A prospective, randomized, double-blind placebo-controlled trial of severely injured (Injury Severity Score [ISS], ≥15) adult patients (aged 18-64 years) admitted to a Level 1 trauma center was conducted. Exclusion criteria included Glasgow Coma Scale score of <14, ISS of <15, pregnancy, and chronic opiate use. All patients were prescribed a patient-controlled analgesia in addition to being randomized to either adjustable dose ketamine starting at 3 μg/kg/min or an equivalent rate of 0.9% normal saline. Study drug and patient-controlled analgesia titration were allowed as part of a treatment algorithm. The primary outcome was reduction in oral morphine equivalent (OME) utilization at 24 hours.
RESULTS: We performed a planned interim analysis upon reaching a predetermined enrollment goal. Forty-two of 78 patients (53.8%) were randomized to the experimental arm. Both groups were similar in makeup and had a median ISS of 22 (19, 28.5). The median OMEs in adjustable dose ketamine and placebo groups were 110.6 (55.7, 191.7) and 99.2 (50.6, 172.6), respectively ( p = 0.85). No significant difference in OME was found in 24- to 48-hour or the entire 48-hour study period. Adjustable dose ketamine had no impact on pain scores throughout the study period when compared with placebo (4.9 vs. 4.7, p = 0.95). These findings met the futility cutoff, and enrollment was terminated.
CONCLUSION: Adjustable dose ketamine failed to reduce OME totals or pain scores in a severely injured trauma cohort when compared with placebo at any time point. Additional studies are necessary to determine if there is any benefit for adjuvant ketamine in different trauma subpopulations.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level I.
参考来源
- Carver TW, Peppard WJ, Gellings JA, et al. Ketamine infusion for pain control in severely injured patients: Results of a randomized controlled trial. J Trauma Acute Care Surg. 2025. PMID: 40152587. doi:10.1097/TA.0000000000004602
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。